Asset Details
Do you wish to reserve the book?
Feasibility of neonatal screening for toxoplasma infection in the absence of prenatal treatment
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Feasibility of neonatal screening for toxoplasma infection in the absence of prenatal treatment
Do you wish to request the book?
Feasibility of neonatal screening for toxoplasma infection in the absence of prenatal treatment
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Feasibility of neonatal screening for toxoplasma infection in the absence of prenatal treatment
1999
Overview
The best method for prevention and control of congenital toxoplasma infection is uncertain. Prenatal screening is done in Austria and France, but the effect of treatment during pregnancy is not well documented. The aim of our study was to find out the maternofetal transmission rate and outcome in infants born to mothers who were not treated during pregnancy.
We analysed 89 873 eluates from phenylketonuria (PKU) cards from neonates and paired first-trimester serum samples from the mothers for specific IgG antibodies to
Toxoplasma gondii. Children born to mothers who seroconverted during pregnancy were followed-up clinically and serologically to 12 months of age. In addition, 21 144 PKU cards were analysed for toxoplasma-specific IgM antibodies during the last 12 months of the study.
In 24 989 (27·8%) cases both the PKU eluate and the first-trimester samples were IgG positive, which indicates previous maternal infection. 139 of the 64 884 seronegative women acquired toxoplasma infection during pregnancy and gave birth to 141 infants (two sets of twins). 27 of these children were diagnosed with congenital toxoplasma infection. The transmission rate was 19·4% (95% CI 13·2–27·0). Clinical signs and symptoms were found in four (15%) of the 27 children. The additional analysis for toxoplasma-specific IgM antibodies from the PKU card identifed seven of nine children with congenital toxoplasma infection. The false-positive rate for the IgM test was 0·19 per 1000, and no false-negatives were found.
The risks of transmission of infection and of disease in the infant are low in an area with a low risk of toxoplasma infection. A neonatal screening programme based on detection of toxoplasma-specific IgM antibodies alone will identify between 70% and 80% of cases of congenital toxoplasmosis.
Publisher
Elsevier Ltd,Lancet,Elsevier Limited
Subject
